Lixisenatide

Lixisenatide is exendin-4(1-39) with the proline at position 38 deleted and six lysine residues appended, which increases receptor affinity and shortens duration. Because it is a short-acting agonist, it does not induce the tachyphylaxis of gastric slowing that long-acting agents show, so its dominant effect is a sustained delay in gastric emptying that flattens postprandial glucose. Fasting glucose and weight effects are correspondingly small. ELIXA was the first GLP-1 cardiovascular outcomes trial and was neutral.

Targets: GLP-1 receptor

• · 10 mcg daily for 14 days, then 20 mcg daily thereafter.

Work out your exact syringe units →

• very commonNausea
• very commonAnti-drug antibodies— Around 70% of patients develop antibodies; high titres reduce efficacy.
• commonVomiting
• commonHypoglycaemia with insulin or sulfonylureas

• History of pancreatitis.
• Severe gastroparesis - a short-acting agent maximally slows gastric emptying.
• Pregnancy.
• eGFR below 15 mL/min/1.73 m2.

• synergyinsulin-analogues — Deliberately paired as Soliqua, a fixed-ratio glargine plus lixisenatide combination.
• redundantsemaglutide — Same receptor.

• · Postprandial glucose specifically.
• · HbA1c.
• · Renal function.

Approved by FDA and EMA; standalone lixisenatide withdrawn from the US market in 2023.

• Pfeffer et al. 2015, ELIXA cardiovascular outcomes trial, NEJM (trial)
• GetGoal phase 3 programme (trial)
• Adlyxin US prescribing information (label)

Lixisenatide exists to prove a specific pharmacological point: with GLP-1 receptor agonists, shorter can be better for one particular endpoint. Long-acting agonists produce continuous receptor occupancy, and the gastric-emptying arm of the response desensitises under continuous exposure within weeks - the satiety and insulinotropic arms do not. Lixisenatide's three-hour half-life means receptor occupancy falls to nothing between doses, the gastric-emptying response never desensitises, and the result is a sustained and profound delay in gastric emptying at whichever meal it precedes. That translates into the best postprandial glucose control in the class and essentially no fasting glucose or weight benefit, which is why it was licensed as a prandial agent and combined with basal insulin as Soliqua rather than used alone. The hexa-lysine tail raises receptor affinity roughly fourfold over exendin-4 while shortening the duration, a combination that looks contradictory until you realise affinity and residence time are separate properties. The immunogenicity is the highest in the class - around 70% of patients develop anti-drug antibodies - which is what happens when you take an already non-human peptide and append a highly charged polylysine tail. ELIXA was the first GLP-1 cardiovascular outcomes trial ever conducted and it was neutral, which at the time was read as reassuring rather than disappointing; in hindsight it fits the pattern that the short-acting exendin-based agents have not shown cardiovascular benefit while the long-acting agents largely have.

People choose it expecting GLP-1 weight loss and get almost none, because it was never designed to produce any. The second failure is timing: it must go in within an hour before the meal, and taken after food it does very little. Third, in severe gastroparesis a short-acting agonist produces maximal gastric-emptying delay with no tachyphylaxis, which is worse than a long-acting agent - the contraindication is not theoretical. Fourth, the standalone product was withdrawn from the US market in 2023, so the practical option is the fixed insulin combination.

1. 10 mcgDays 1-14 — Within one hour before the same meal each day.
2. 20 mcgDay 15 onward — Maintenance dose. There is no further step.

• GLP-1 receptor (GLP1R) — Roughly four-fold higher affinity than exendin-4, commonly reported but not re-verified here

  Short, intense receptor occupancy producing non-tachyphylactic gastric-emptying delay and glucose-dependent insulin secretion, with minimal chronic central satiety signalling.

• ELIXA Phase 3 cardiovascular outcomes · n=6068 · 108 weeks · 2015

  Neutral for major adverse cardiovascular events after a recent acute coronary syndrome - the first GLP-1 cardiovascular outcomes trial to report.

Acts on the meal it precedes, within the hour. Steady state within a day. Full glycaemic benefit within one to two weeks. Stopping has an immediate effect - there is no depot.

The one pairing that makes sense is basal insulin, and it is licensed as exactly that - Soliqua combines insulin glargine with lixisenatide in a fixed ratio because basal insulin handles fasting glucose and lixisenatide handles the postprandial excursion. It is redundant with every other GLP-1 agonist and specifically redundant with exenatide, which it essentially is. There is no case for using it as a weight-loss agent alongside anything.

Against exenatide immediate-release: essentially the same molecule with a lysine tail, once daily instead of twice, higher affinity, higher immunogenicity. Against every long-acting agonist: lixisenatide loses on weight, on fasting glucose and on convenience, and wins only on postprandial glucose because it is the one agent whose gastric-emptying effect does not desensitise. It is best understood as a pharmacological demonstration rather than a therapeutic choice.

Standalone lixisenatide was withdrawn from the US market in 2023. Soliqua pricing depends entirely on the insulin component and on coverage; no reliable standalone figure exists.

• ?Volume of distribution and absolute bioavailability are not reported in the Soliqua label and were left null rather than estimated.
• ?The four-fold affinity advantage over exendin-4 is widely cited but was not independently verified in this session.
• ?The reported 70% anti-drug antibody incidence comes from the original registration programme and varies by assay.
• ?Whether ELIXA's neutrality reflects the short-acting profile, the post-acute-coronary-syndrome population or simply insufficient exposure has never been resolved.

• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome Pfeffer MA et al., N Engl J Med, 2015 · PMID 26630143

  ELIXA. The first cardiovascular outcomes trial in the class, and neutral.

• SOLIQUA 100/33 (insulin glargine and lixisenatide) injection - US prescribing information, section 12.3 Sanofi-Aventis U.S. LLC, DailyMed

  Source for the 2.5-3.0 hour tmax, 55% protein binding, 35 L/h clearance and glomerular filtration elimination route.